A Phase 4 interventional study of Low intensity shockwave therapy and Oral Solifenacin succinate 5 mg in Overactive Bladder (OAB) and Urge Incontinence, sponsored by Mansoura University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Mansoura University · Phase 4, Interventional, and Treatment
Among 23 studies in Urinary Bladder, Overactive with a site in Egypt — 7 open to participants now, 8 under way, 1 of them phase 3. Urinary Bladder, Overactive · Egypt.
Among the 23 studies in Urinary Bladder, Overactive with a site in Egypt, this one is the 12th largest by planned enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2025, is one of 5 in phase 4, and was the 20th registered.
858 studies on the registry are indexed under Urinary Bladder, Overactive; 126 are open to participants now.
Browse Urinary Bladder, Overactive studies →7 of the 23 studies in Urinary Bladder, Overactive with a site in Egypt are open now. Recruiting first, the newest first:
Mansoura University · Sites in Egypt
Ages 18–75 · Women only
Cairo University · Sites in Egypt
Ages 50–60 · Women only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Women only
Mansoura University · Sites in Egypt
Ages 18+ · Women only
Cairo University · Sites in Egypt
Ages 20–50
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 73 Urinary Bladder, Overactive studies recruiting now, 44 (60%) set no upper age limit and 15 (21%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 70 across 649 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 74 across the 21 interventional studies, 512 across the 2 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 23 have an industry lead sponsor. The 10 most frequent:
Mansoura University is the lead sponsor of 1,119 studies on the registry; 183 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Mansoura University has 7 studies filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
3 of the studies in Urinary Bladder, Overactive with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07693192Mahmoud Mohamed Farag AliComparative Efficacy and Safety if Intravesical Botulinum Toxin A Versus Platelet-Rich Plasma in the Management of Refractory Overactive Bladder : A 2 Year Study | 2026-12-01 |
| NCT07739550Al-Azhar UniversityLow-Intensity Shock Wave Therapy for Refractory Overactive Bladder in Women | 2027-02-01 |
| NCT07473310Mansoura UniversityLow-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Urinary Bladder, Overactive with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the effectiveness and safety of low-intensity shockwave therapy (Li-SWT) for the treatment of overactive bladder (OAB) in adult women.
The main questions this study aims to answer are whether Li-SWT improves overactive bladder symptoms and quality of life, and whether these improvements are sustained over a 12-month follow-up period, compared with standard medical therapy.
Researchers will compare Li-SWT with oral solifenacin succinate, a commonly used antimuscarinic medication for OAB.
Participants will be randomly assigned to receive either Li-SWT once weekly for 8 weeks or solifenacin 5 mg taken orally once daily for 12 months. All participants will complete symptom questionnaires and three-day voiding diaries and will undergo uroflowmetry, post-void residual measurement, and filling cystometry at specified time points during follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allocated to receive LiSWT
Other: Low intensity shockwave therapy
Allocated to receive oral Solifenacin succinate 5 mg
Drug: Oral Solifenacin succinate 5 mg
Participants will receive Li-SWT which will be applied once weekly for 8 weeks, with a focused shockwave. The bladder will be scanned by US to ensure that t is filled with approximately 50% of the maximum cytometric capacity as measure by baseline cystometry. The patients will be asked to lie flat in a supine position. The device will be operated by a well-trained urologist. A commercially used gel for sonography will be applied to suprapubic region. The applicator will be applied to the S.P region in 3 horizontal sites. 2 cm from each other and 2 fingerbreadths above the pubic bone with 45° tilt. Li-SWT will be applied with energy density of 0.12 mJ/mm² and frequency of 4 pulses/second for a total of 3000 pulses per session (1000 pulses per bladder dome and each lateral wall at 45° tilt).
Participants will receive solifenacin succinate 5 orally once daily for 12 months
Changes in Overactive Bladder Symptom Score (OABSS) from baseline to different points of follow up
self administered questionnaire with minimum score of 0 and maximum score of 15, higher score means worse symptoms
Time frame: Baseline and 3 months
Changes in frequency on three-day urinary diary
Changes in the mean number of voiding episodes per days as measure by a self administered three-day urinary diary
Time frame: from baseline to 1, 3, 6,9 and 12 months
Changes in number of urgency episodes on three-day urinary diary
Changes in the mean number of urgency episodes per day (strong desire to void that cannot be postponed or withheld) as measured by a self administered three-day voiding diary
Time frame: baseline to 1, 2, 3,6,9 and 12 months
Changes in number of nocturia episodes on three-day urinary diary
changes in the mean number of nocturia episodes per night(waking up in the middle of the night to void) as measured by a self-administered three-day voiding diary
Time frame: baseline to 1, 2, 3,6,9 and 12 months
Changes in number of incontinence episodes on three-day urinary diary
Changes in number of incontinence episodes per day (involuntary leakage of urine) as measured by a self administered three-day urinary diary
Time frame: form baseline to 1,2,3,6,9 and 12 months
changes in International Consultation on Incontinence Questionnaire- Urinary Incontinence-Short Form (ICIQ-UI-SF) score
self administered questionnaire with minimum score of 0 and maximum score of 21, the higher score, the worse the symptoms
Time frame: form baseline to 1,2,3,6,9 and 12 months
changes in Overactive bladder quality of life questionnaire (ICIQ-OABqol)
self administered questionnaire with minimum score of 25 and maximum score of 160 , higher score indicated worse effect on the quality of life
Time frame: from baseline to 1,2,3,6,9 and 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jun 2027, 19 months after the start.
Of 42 non-industry phase 4 interventional studies under Urinary Bladder, Overactive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 19 months is below that.
Counting every sponsor, half of 54 studies reached it within 23 months; a quarter within 15 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.